Spark Newswire Spark Newswire
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
News by Category
  • After-Hours Center
  • Analyst Color
  • Analyst Ratings
  • Asia
  • Asset Sales
  • Binary Options
  • Biotech
  • Bonds
  • Broad U.S. Equity ETFs
  • Buybacks
  • Cannabis
  • Commodities
  • Contracts
  • Crowdsourcing
  • Cryptocurrency
  • Currency ETFs
  • Dividends
  • Downgrades
  • Earnings
  • Earnings Beats
  • Earnings Misses
  • Econ #s
  • Economics
  • Education
  • Emerging Market ETFs
  • Emerging Markets
  • Entertainment
  • Entrepreneurship
  • Equities
  • ESG
  • ETFs
  • Eurozone
  • Events
  • Exclusives
  • FDA
  • Federal Reserve
  • Financial Advisors
  • Financing
  • Fintech
  • Forex
  • Futures
  • Gaming
  • General
  • Global
  • Government
  • Guidance
  • Health Care
  • Hedge Funds
  • Hot
  • Initiation
  • Insider Trades
  • Insurance
  • Interview
  • Intraday Update
  • IPOs
  • Large Cap
  • Latin America
  • Legal
  • Long Ideas
  • M&A
  • Macro Economic Events
  • Macro Notification
  • Management
  • Market Summary
  • Market-Moving Exclusives
  • Markets
  • Media
  • Mid Cap
  • Mining
  • Movers
  • Movers & Shakers
  • Mutual Funds
  • New ETFs
  • News
  • Offerings
  • Opinion
  • Options
  • Penny Stocks
  • Personal Finance
  • Politics
  • Pre-Market Outlook
  • Press Releases
  • Previews
  • Price Target
  • Psychedelics
  • Psychology
  • Real Estate
  • Regulations
  • REIT
  • Reiteration
  • Restaurants
  • Retail Sales
  • Reviews
  • Rumors
  • SEC
  • Sector ETFs
  • Short Ideas
  • Short Sellers
  • Signals
  • Small Business
  • Small Cap
  • Small Cap Analysis
  • Small-Cap
  • Social Media
  • SPACE
  • Specialty ETFs
  • Sports
  • Sports Betting
  • Startups
  • Stock Split
  • Success Stories
  • Tech
  • Technicals
  • Termination
  • Top Stories
  • Topics
  • Trading Ideas
  • Travel
  • Treasuries
  • Uncategorized
  • Upgrades
Spark Newswire Spark Newswire
Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
Spark Newswire Spark Newswire
Filter By Ticker
Search By Date To
Today | Yesterday | This week
Browsing Category

Biotech

Biotech

Group By Ticker
Sort By
Newest | Oldest
Read More
2 minute read
  • Biotech
  • General
  • News

Neurocrine Biosciences To Present Phase 3 Baseline Characteristics Data From The CAHtalyst Program Of Crinecerfont In CAH, And Data For Modified-Release Hydrocortisone In Primary Adrenal Insufficiency And CAH Studies At ECE 2024

By Benzinga Newsdesk
May 7, 8:38 AM
CAHtalyst™ Pediatric and CAHtalyst™ Adult Baseline Characteristics Data in Congenital Adrenal HyperplasiaPhase 2 (CHAMPAIN) Clinical Study Data for Modified-Release Hydrocortisone

NBIX

Read More
2 minute read
  • Biotech
  • General
  • News

Precision BioSciences Announces Receipt Of FDA Fast Track Designation For ECUR-506, iECURE’s Program For The Treatment Of Neonatal Onset Ornithine Transcarbamylase Deficiency

By Benzinga Newsdesk
May 7, 8:37 AM
Precision BioSciences, Inc. (NASDAQ:DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene

DTIL

Read More
2 minute read
  • Biotech
  • General
  • News

Mirum Announces Publication Of Phase 3 MARCH Data In The Lancet Demonstrating Benefits Of LIVMARLI In patients With PFIC

By Benzinga Newsdesk
May 7, 8:30 AM
- Data demonstrate significant benefit across broadest range of genetic PFIC types ever studied- Significant improvements observed across multiple parameters including pruritus, serum bile acids, growth and

MIRM

Read More
2 minute read
  • Biotech
  • General
  • Global
  • News

Oragenics Partners with Avance Clinical For Phase II Concussion Trial In Australia

By Benzinga Newsdesk
May 7, 8:22 AM
Oragenics, Inc. (NYSE:OGEN), a pioneer in developing innovative intranasal pharmaceuticals for neurological disorders, today announced a partnership with Avance Clinical, a leading Contract Research Organization (CRO),

OGEN

Read More
2 minute read
  • Biotech
  • General
  • News

Actinium Announces KOL Webinar To Highlight Recently Announced Iomab-ACT Trial With Leading FDA Approved Commercial CAR T-Cell Therapy Being Led By The University Of Texas Southwestern

By Benzinga Newsdesk
May 7, 8:21 AM
Dr. Farrukh Awan, Professor of Medicine, Division of Hematology Oncology at University of Texas Southwestern and Principal Investigator for the trial to join Actinium management for webinarExpansion of Iomab-ACT program

ATNM

Read More
3 minute read
  • Biotech
  • General
  • News

ImmunityBio Completes GMP Drug Substance Manufacturing Sufficient For 170,000 Doses Of ANKTIVA

By Benzinga Newsdesk
May 7, 8:18 AM
ANKTIVA® Drug Substance completed and released with two-year storage stability data sufficient for 170,000 doses of ANKTIVA productImmunityBio's 400,000 square foot GMP fill-finish facility in Dunkirk, New York on

IBRX

Read More
2 minute read
  • Biotech
  • General
  • News

Ardelyx To Present Additional Data Supporting First-In-Class IBSRELA For Adults With Irritable Bowel Syndrome With Constipation At The 2024 Digestive Disease Week Conference

By Benzinga Newsdesk
May 7, 8:13 AM
Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that

ARDX

Read More
1 minute read
  • Biotech
  • General
  • News

Alimera Announces Scientific Data Highlighting YUTIQ To Be Presented At Upcoming Association For Research In Vision And Ophthalmology And Retina World Congress Conferences

By Benzinga Newsdesk
May 7, 8:11 AM
Alimera Sciences, Inc. (NASDAQ:ALIM) ("Alimera"), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer,

ALIM

Read More
2 minute read
  • Biotech
  • General
  • News

Aspira Women’s Health Announces Publication Of Two OvaWatch Peer-Reviewed Manuscripts

By Benzinga Newsdesk
May 7, 8:10 AM
Aspira Women's Health Inc. ("Aspira" or the "Company") (NASDAQ:AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced the publication of

AWH

Read More
3 minute read
  • Biotech
  • General
  • News

Traws Pharma Completes First Cohort Dosed In Phase 1 Trial For COVID Therapy

By Benzinga Newsdesk
May 7, 8:09 AM
Investigational travatrelvir demonstrated preclinical activity against multiple SARS-CoV-2 variants Orally administered novel protease inhibitor does not require ritonavir co-administrationFirst-in-Human study to

TRAW

Posts pagination

Previous 1 … 39 40 41 … 733 Next
Free Newsletter subscribe

Stock Market Ideas & Analysis

Stay up-to-date with the same information professionals use.
Spark Newswire Spark Newswire
  • Newswire
  • Registration
  • Log In
  • Settings
  • Privacy Policy
  • Terms of Service
© 2021 Spark Newswire
All Rights Reserved.

All news is property of their respective owners. Terms of Service